.
MergerLinks Header Logo

Announced

Completed

Inflexion completed the investment in Proteros biostructures.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Germany

Private

Single Bidder

Minority

Acquisition

Pharmaceuticals

Friendly

drug discovery

Cross Border

Private Equity

Completed

Synopsis

Edit

Inflexion, a mid-market private equity firm, completed the investment in Proteros biostructures, a contract research organization focused on early-stage drug discovery. Financial terms were not disclosed. “I am excited to have Inflexion on board as a partner. Their track record in backing innovative businesses combined with their operational experience within all areas of rapidly growing companies gives me great conviction they are well placed to support Proteros in its further growth trajectory," Torsten Neuefeind, Proteros Founder and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US